May 30, 2013
11:30 am to 12:30 PM EDT

Sponsored by

Symposium Course Description:

The drug development process is witnessing a paradigm shift in which new therapies need to be tailored to well defined patient sub-groups via a companion diagnostic assay. The paradigm shift to develop these new precision medicines creates significant opportunities to exploit innovative diagnostic technologies from biomarker discovery through to commercialization. Here we will address some of the key considerations to achieve successful development and commercialization of companion diagnostic products.

Learning Objectives:

  • Understand Single Molecule Array (Simoa) technology and its application for translational and clinical researchers who wish to quantify and validate low abundance protein biomarkers to improve the drug discovery process, make clinical trials more efficient and informative, and individualize therapy

Who Will Benefit:

  • Healthcare professionals seeking to gain an overview on the personalized medicine landscape and state of diagnostic technology capabilities
  • Scientists active in biomarker research seeking technologies for implementation of their biomarkers
  • Drug developers wishing to explore partnering opportunities with companion diagnostic test technology developers
  • Laboratories currently utilizing immunoassays for discovery, preclinical studies and clinical trials that desire the highest sensitivity and precision, and the ability to generate data rapidly for increased productivity
  • Pre-clinical and clinical researchers specializing in Assay Development, Biomarkers, Diagnostics, Proteins and Proteomics, Translational Medicine, Personalized Medicine and Companion Diagnostics

Program Agenda (with time):

1. Introduction to Quanterix Single Molecule Array (Simoa) technology (15 min)

  • Presentation by Dr. David Duffy, Quanterix Corporation

2. Key Considerations for Development and Commercialization of Companion Diagnostic Assays: Perspectives from a Global IVD Leader (35 min)

  • Presentation by Dr. John Beeler, bioMerieux

3. Q&A (5-10 min)

Speaker Information:

Speaker #1 Information:

David Duffy, Ph.D.

Vice President, Research and Chief Technology Officer

Quanterix Corporation
113 Hartwell Avenue
Lexington, MA 02421
Tel: 617-301-9412

Speaker #2 Information:

John F. Beeler Ph.D.

Director, Theranostics and Business Development

5 Cambridge Center
Suite 0802
Cambridge, MA 02142
Tel: 617-679-8006